These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 23063998

  • 1. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
    Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW.
    Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
    [Abstract] [Full Text] [Related]

  • 2. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [Abstract] [Full Text] [Related]

  • 3. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [Abstract] [Full Text] [Related]

  • 4. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A, Herbst U, Manalang J, Pather S, Saidi S, Tejada-Berges T, Tan K, Williams P, Carter J.
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, Yamada K, Takano H, Sasaki H, Koyama K, Ochiai K.
    Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
    [Abstract] [Full Text] [Related]

  • 7. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, Kyung MS.
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [Abstract] [Full Text] [Related]

  • 8. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL, Wang CJ, Qi P, Zhang YX.
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [Abstract] [Full Text] [Related]

  • 9. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC.
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [Abstract] [Full Text] [Related]

  • 10. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, Australian Ovarian Cancer Study Group, Obermair A.
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [Abstract] [Full Text] [Related]

  • 11. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z, Tao X, Ying C.
    Dis Markers; 2019 Jun; 2019():6241743. PubMed ID: 31737130
    [Abstract] [Full Text] [Related]

  • 12. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B, Fuksiewicz M, Sobiczewski P, Spiewankiewicz B, Jonska-Gmyrek J, Skrzypczak M, Kowalska M.
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [Abstract] [Full Text] [Related]

  • 13. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A.
    Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
    [Abstract] [Full Text] [Related]

  • 14. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M, Kristjansdottir B, Sundfeldt K.
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [Abstract] [Full Text] [Related]

  • 15. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
    Shipeng G, Yongning C, Yadi Z, Chanyuan LI, Qifan J.
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec 30; 39(12):1393-1401. PubMed ID: 31907150
    [Abstract] [Full Text] [Related]

  • 16. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
    Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L, Chen M.
    BMC Cancer; 2012 Jun 19; 12():258. PubMed ID: 22712526
    [Abstract] [Full Text] [Related]

  • 17. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
    Wang Q, Wu Y, Zhang H, Yang K, Tong Y, Chen L, Zhou Q, Guan S.
    Clin Lab; 2019 Apr 01; 65(4):. PubMed ID: 30969083
    [Abstract] [Full Text] [Related]

  • 18. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
    Yanaranop M, Jantarateptewan N, Tiyayon J, Nakrangsee S.
    Int J Gynecol Cancer; 2018 Jul 01; 28(6):1058-1065. PubMed ID: 29975290
    [Abstract] [Full Text] [Related]

  • 19. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
    Terlikowska KM, Dobrzycka B, Witkowska AM, Mackowiak-Matejczyk B, Sledziewski TK, Kinalski M, Terlikowski SJ.
    J Ovarian Res; 2016 Jul 19; 9(1):43. PubMed ID: 27436085
    [Abstract] [Full Text] [Related]

  • 20. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM.
    Diagn Pathol; 2013 Jan 23; 8():11. PubMed ID: 23343214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.